Clinical Trial Update: Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial from Norgine evaluated the safety and preliminary response of 1 or 2 g rectal suppositories containing 5 or 10 mg NRL001 for fecal inco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fecal Incontinence

Drugs mentioned

• NRL001

Snippet

Sponsor: Norgine | Conditions: Fecal Incontinence | Phase 1 | Status: COMPLETED